Search clinical trials for: elamipretide (MTP-131) 1% topical ophthalmic solution

Total 248 results

Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Leber's Hereditary Optic Neuropathy

United States
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) (SPIFD-101)

Fuchs' Corneal Endothelial Dystrophy (FCED)

United States
Stealth BioTherapeutics Inc.
ICON Clinical Research

Completed

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events (EMBRACE)

Reperfusion Injury | STEMI

United States, Hungary, Germany, Poland
Stealth BioTherapeutics Inc.

Completed

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly (MOTION)

Skeletal Muscle Mitochondrial Dysfunction in the Elderly

United States
Stealth BioTherapeutics Inc.

Completed

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Stealth BioTherapeutics Inc.

Available

An Intermediate Size Expanded Access Protocol of Elamipretide

Mitochondrial Diseases | Barth Syndrome
Stealth BioTherapeutics Inc.

Completed

A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

Heart Failure

Spain, Hungary, Netherlands, United Kingdom, Serbia, France, Latvia, Belgium, Bulgaria, Poland
Stealth BioTherapeutics Inc.

Completed

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study (MMPOWER-2)

Primary Mitochondrial Disease

United States
Stealth BioTherapeutics Inc.
Charite University, Berlin, Germany; SCIRENT Clinical Research and Science...

Completed

A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

Chronic Heart Failure

Germany, Serbia
Stealth BioTherapeutics Inc.

Completed

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER)

Barth Syndrome

United States
Children's Hospital of Philadelphia
Friedreich's Ataxia Research Alliance; Stealth BioTherapeutics Inc.

Active, not recruiting

FRDA Investigator Initiated Study (IIS) With Elamipretide (ELViS-FA)

Friedreich Ataxia

United States
Stealth BioTherapeutics Inc.

Terminated

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery (EVOLVE)

Renal Artery Obstruction | Ischemia Reperfusion Injury | Hypertension, Renovascular

United States
Stealth BioTherapeutics Inc.

Completed

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy (MMPOWER)

Mitochondrial Myopathy

United States
Stealth BioTherapeutics Inc.

Active, not recruiting

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) (NuPower)

Mitochondrial Diseases | Mitochondrial Myopathies | Mitochondrial Complex I Deficiency | Mitochondrial Pathology | Mitochondrial DNA Depletion | Mitochondrial DNA Mutation | Mitochondrial DNA Deletion | Mitochondrial Metabolism Defect

Spain, United States, Italy, Netherlands, Australia, Germany, Hungary, New Zealand, Norway, United Kingdom
Stealth BioTherapeutics Inc.

Terminated

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension (MMPOWER-3)

Primary Mitochondrial Myopathy

United States, Germany, Canada, Italy, United Kingdom, Denmark, Hungary
Stealth BioTherapeutics Inc.

Completed

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Heart Failure

Netherlands, Italy, United Kingdom
Stealth BioTherapeutics Inc.

Completed

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA (ReCLAIM-2)

Age-related Macular Degeneration

United States
MacuCLEAR, Inc.

Unknown

Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration (McCP2/3)

Non-Exudative Age Related Macular Degeneration

United States
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration

United States
Ophthalmic Consultants of Long Island
Pfizer

Completed

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Dry Eye Disease

United States
Qlaris Bio, Inc.

Completed

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Ocular Hypertension | Glaucoma | Sturge-Weber Syndrome

United States
Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Qlaris Bio, Inc.

Completed

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Ocular Hypertension | Glaucoma | Glaucoma Congenital | Sturge-Weber Syndrome (SWS)

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Keratoconjunctivitis Sicca

United States
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma or Ocular Hypertension

Japan
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
Iacta Pharmaceuticals

Recruiting

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

Dry Eye Syndromes

United States
Stealth BioTherapeutics Inc.

Completed

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration (SPIOC-101)

Age-related Macular Degeneration | Diabetic Macular Edema

United States
VivaVision Biotech, Inc

Completed

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

Dry Eye

United States
American Genomics, LLC

Completed

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Healthy

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Common Wart

United States
Yuyu Pharma, Inc.

Active, not recruiting

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Dry Eye

United States
Qlaris Bio, Inc.

Recruiting

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Glaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)

United States
pH Pharma

Completed

PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects

Healthy Volunteer

Korea, Republic of
Qlaris Bio, Inc.

Recruiting

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Primary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Dermatosis Papulosa Nigra

United States
Glaukos Corporation

Recruiting

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United States
Aclaris Therapeutics, Inc.

Completed

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (SK-FAN)

Seborrheic Keratosis

United States
Alcon Research

Completed

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
University of Maryland, Baltimore
Aerie Pharmaceuticals

Completed

Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Ocular Hypertension | Suspect Glaucoma

United States
Merck Sharp & Dohme LLC

Terminated

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Posterior Blepharoconjunctivitis

United States
Merck Sharp & Dohme LLC

Completed

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Blepharitis

United States

3

Subscribe